DURECT Corporation (DRRX)
USD 0.79
(0.92%)
USD 0.79
(0.92%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.7 Million USD | -83.27% |
| 2022 | 16.15 Million USD | -28.06% |
| 2021 | 22.45 Million USD | -2.95% |
| 2020 | 23.13 Million USD | -6.62% |
| 2019 | 24.77 Million USD | 20.68% |
| 2018 | 20.53 Million USD | 62.52% |
| 2017 | 12.63 Million USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 19.68 Million USD | -0.71% |
| 2014 | 19.82 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 100.0% |
| 2011 | -30.09 Million USD | 13.66% |
| 2010 | -34.84 Million USD | -6960.04% |
| 2009 | 508 Thousand USD | -22.56% |
| 2008 | 656 Thousand USD | 155.25% |
| 2007 | 257 Thousand USD | -99.32% |
| 2006 | 37.94 Million USD | -40.88% |
| 2005 | 64.18 Million USD | 5.33% |
| 2004 | 60.93 Million USD | -0.71% |
| 2003 | 61.37 Million USD | 4350.47% |
| 2002 | 1.37 Million USD | -30.91% |
| 2001 | 1.99 Million USD | 80.63% |
| 2000 | 1.1 Million USD | 484.66% |
| 1999 | 189 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.22 Million USD | 0.0% |
| 2024 Q1 | 2.46 Million USD | -100.0% |
| 2023 Q2 | 803 Thousand USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q4 | 2.7 Million USD | -7.69% |
| 2023 FY | 2.7 Million USD | -83.27% |
| 2023 Q3 | 2.92 Million USD | 264.51% |
| 2022 FY | 16.15 Million USD | -28.06% |
| 2022 Q1 | 22.2 Million USD | -1.11% |
| 2022 Q3 | 18.56 Million USD | -11.54% |
| 2022 Q2 | 20.98 Million USD | -5.49% |
| 2022 Q4 | 16.15 Million USD | -12.99% |
| 2021 Q1 | 20.94 Million USD | -9.49% |
| 2021 FY | 22.45 Million USD | -2.95% |
| 2021 Q4 | 22.45 Million USD | -1.01% |
| 2021 Q2 | 22.9 Million USD | 9.35% |
| 2021 Q3 | 22.68 Million USD | -0.94% |
| 2020 Q3 | 24.18 Million USD | -0.73% |
| 2020 Q1 | 24.58 Million USD | -0.8% |
| 2020 FY | 23.13 Million USD | -6.62% |
| 2020 Q4 | 23.13 Million USD | -4.34% |
| 2020 Q2 | 24.36 Million USD | -0.88% |
| 2019 Q4 | 24.77 Million USD | 8.65% |
| 2019 Q2 | 24.98 Million USD | -4.32% |
| 2019 Q1 | 26.11 Million USD | 27.16% |
| 2019 Q3 | 22.8 Million USD | -8.71% |
| 2019 FY | 24.77 Million USD | 20.68% |
| 2018 Q3 | 9.5 Million USD | -23.02% |
| 2018 FY | 20.53 Million USD | 62.52% |
| 2018 Q1 | 15.17 Million USD | 20.14% |
| 2018 Q2 | 12.34 Million USD | -18.69% |
| 2018 Q4 | 20.53 Million USD | 116.14% |
| 2017 Q2 | 16.61 Million USD | -10.68% |
| 2017 Q1 | 18.59 Million USD | 0.0% |
| 2017 FY | 12.63 Million USD | 0.0% |
| 2017 Q3 | 14.62 Million USD | -11.97% |
| 2017 Q4 | 12.63 Million USD | -13.6% |
| 2016 Q3 | 19.83 Million USD | 0.44% |
| 2016 Q1 | 17.89 Million USD | -9.1% |
| 2016 Q2 | 19.75 Million USD | 10.4% |
| 2016 Q4 | - USD | -100.0% |
| 2016 FY | - USD | -100.0% |
| 2015 Q3 | 19.65 Million USD | -1.07% |
| 2015 Q4 | 19.68 Million USD | 0.17% |
| 2015 FY | 19.68 Million USD | -0.71% |
| 2015 Q1 | 18.01 Million USD | -9.12% |
| 2015 Q2 | 19.86 Million USD | 10.24% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | 19.78 Million USD | 0.0% |
| 2014 FY | 19.82 Million USD | 0.0% |
| 2014 Q3 | 19.8 Million USD | 0.1% |
| 2014 Q4 | 19.82 Million USD | 0.1% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q1 | -1.71 Million USD | 94.3% |
| 2012 Q2 | -1.63 Million USD | 4.55% |
| 2012 FY | - USD | 100.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 100.0% |
| 2011 Q3 | -31.93 Million USD | -3.65% |
| 2011 FY | -30.09 Million USD | 13.66% |
| 2011 Q4 | -30.09 Million USD | 5.77% |
| 2011 Q2 | -30.8 Million USD | 6.15% |
| 2011 Q1 | -32.82 Million USD | 5.8% |
| 2010 Q3 | -36.86 Million USD | 5.19% |
| 2010 FY | -34.84 Million USD | -6960.04% |
| 2010 Q2 | -38.88 Million USD | -136.69% |
| 2010 Q4 | -34.84 Million USD | 5.48% |
| 2010 Q1 | -16.43 Million USD | -3334.25% |
| 2009 Q4 | 508 Thousand USD | 102.77% |
| 2009 FY | 508 Thousand USD | -22.56% |
| 2009 Q1 | 667 Thousand USD | 1.68% |
| 2009 Q2 | 614 Thousand USD | -7.95% |
| 2009 Q3 | -18.36 Million USD | -3091.21% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | 656 Thousand USD | 155.25% |
| 2008 Q4 | 656 Thousand USD | 0.0% |
| 2007 Q2 | 37.8 Million USD | -0.35% |
| 2007 FY | 257 Thousand USD | -99.32% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q1 | 37.93 Million USD | -0.02% |
| 2007 Q3 | 578 Thousand USD | -98.47% |
| 2006 Q4 | 37.94 Million USD | -0.57% |
| 2006 Q3 | 38.16 Million USD | -0.02% |
| 2006 Q2 | 38.17 Million USD | -34.35% |
| 2006 Q1 | 58.14 Million USD | -9.42% |
| 2006 FY | 37.94 Million USD | -40.88% |
| 2005 Q2 | 68.64 Million USD | 12.7% |
| 2005 Q3 | 58.24 Million USD | -15.16% |
| 2005 Q4 | 64.18 Million USD | 10.21% |
| 2005 FY | 64.18 Million USD | 5.33% |
| 2005 Q1 | 60.9 Million USD | -0.04% |
| 2004 Q3 | 61.19 Million USD | -0.05% |
| 2004 Q4 | 60.93 Million USD | -0.43% |
| 2004 FY | 60.93 Million USD | -0.71% |
| 2004 Q1 | 61.3 Million USD | -0.12% |
| 2004 Q2 | 61.23 Million USD | -0.12% |
| 2003 Q1 | 1.76 Million USD | 27.92% |
| 2003 FY | 61.37 Million USD | 4350.47% |
| 2003 Q2 | 51.69 Million USD | 2830.5% |
| 2003 Q3 | 1.62 Million USD | -96.86% |
| 2003 Q4 | 61.37 Million USD | 3681.39% |
| 2002 Q3 | 1.63 Million USD | -5.65% |
| 2002 Q4 | 1.37 Million USD | -15.71% |
| 2002 Q1 | 1.96 Million USD | -1.65% |
| 2002 Q2 | 1.73 Million USD | -11.67% |
| 2002 FY | 1.37 Million USD | -30.91% |
| 2001 FY | 1.99 Million USD | 80.63% |
| 2001 Q4 | 1.99 Million USD | -12.42% |
| 2001 Q3 | 2.27 Million USD | -4.96% |
| 2001 Q2 | 2.39 Million USD | 149.53% |
| 2001 Q1 | 961 Thousand USD | -13.03% |
| 2000 FY | 1.1 Million USD | 484.66% |
| 2000 Q3 | 923 Thousand USD | 24.73% |
| 2000 Q4 | 1.1 Million USD | 19.72% |
| 2000 Q2 | 740 Thousand USD | 0.0% |
| 1999 FY | 189 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | 10.982% |
| Safety Shot Inc | 304.9 Thousand USD | -786.172% |
| Bright Green Corporation | 201.78 Thousand USD | -1239.062% |
| Embecta Corp. | 1.62 Billion USD | 99.834% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.127% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 97.033% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.449% |
| Dynavax Technologies Corporation | 252.41 Million USD | 98.93% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.461% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 79.724% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.474% |
| PainReform Ltd. | 30 Thousand USD | -8906.667% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -401.266% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -401.266% |
| SCYNEXIS, Inc. | 12.15 Million USD | 77.778% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -2206.858% |
| Journey Medical Corporation | 14.62 Million USD | 81.521% |
| Alpha Teknova, Inc. | 13.25 Million USD | 79.609% |
| Procaps Group, S.A. | 28.41 Million USD | 90.489% |
| Theratechnologies Inc. | 51.26 Million USD | 94.729% |
| Harrow Health, Inc. | 183.17 Million USD | 98.525% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -3005.747% |
| Biofrontera Inc. | 804 Thousand USD | -236.07% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 91.86% |
| Cronos Group Inc. | 1.55 Million USD | -73.316% |
| OptiNose, Inc. | 611 Thousand USD | -342.226% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.458% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 92.097% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -493.846% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 95.552% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 78.864% |
| Radius Health, Inc. | 339.66 Million USD | 99.205% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 73.66% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.41% |
| Procaps Group S.A. | 28.41 Million USD | 90.489% |
| Alvotech | 1.02 Billion USD | 99.737% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 58.634% |
| Viatris Inc. | 16.18 Billion USD | 99.983% |
| Rockwell Medical, Inc. | 8.29 Million USD | 67.418% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 75.159% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -704.188% |
| Tilray Brands, Inc. | 287.93 Million USD | 99.062% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 97.758% |
| Shineco, Inc. | 10.01 Million USD | 73.027% |
| PetIQ, Inc. | 437.82 Million USD | 99.383% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -1186.667% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 98.954% |
| Alimera Sciences, Inc. | 64.48 Million USD | 95.81% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 92.984% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -1900.163% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 60.597% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -275.278% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -11917.435% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 91.752% |
| Hempacco Co., Inc. | 5.93 Million USD | 54.443% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.737% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 95.194% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.561% |
| Currenc Group, Inc. | 2.5 Million USD | -7.779% |
| Kamada Ltd. | 7.43 Million USD | 63.673% |
| Indivior PLC | 235.66 Million USD | 98.853% |
| Evoke Pharma, Inc. | 5 Million USD | 45.96% |
| Flora Growth Corp. | 942 Thousand USD | -186.837% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -11917.435% |
| Evolus, Inc. | 120.35 Million USD | 97.755% |
| HUTCHMED (China) Limited | 48.18 Million USD | 94.393% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.541% |
| Akanda Corp. | 2.49 Million USD | -8.203% |